Bank of Montreal Files FWP Prospectus

TL;DR

BMO filed an FWP on 4/7/26. Standard prospectus stuff.

AI Summary

On April 7, 2026, Bank of Montreal filed a Free Writing Prospectus (FWP) under Securities Act Rules 163/433. This filing, with accession number 0001214659-26-004400, is a standard regulatory submission related to potential future offerings. The filing includes a 983-page document titled 'PSARC' and a graphic file.

Why It Matters

This FWP filing by Bank of Montreal indicates potential future capital raising activities or the offering of new securities, which could impact its financial structure and investor base.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (FWP) and does not indicate any immediate or specific financial distress or significant event.

Key Numbers

• 983 — pages (Length of the PSARC document within the FWP filing)

Key Players & Entities

• Bank of Montreal (company) — Subject of the filing
• 0000927971 (company) — CIK number for Bank of Montreal
• 0001214659-26-004400 (dollar_amount) — SEC Accession Number for the filing
• 2026-04-07 (dollar_amount) — Filing Date

FAQ

Key Financial Figures

• $5,000 — l be issued in minimum denominations of $5,000 and integral multiples of $5,000. &mi
• $4,900.00 — notes in these accounts may be between $4,900.00 and $5,000 per $5,000 in principal amou
• $4,863.50 — estimated initial value of the notes is $4,863.50 per $5,000 in principal amount. The est
• $4,625.00 — om this value but will not be less than $4,625.00 per $5,000 in principal amount. However
• $29.165 — m). Accordingly, each Coupon will equal $29.165 for each $5,000 in principal amount.

Filing Documents

• p47261fwp.htm (FWP) — 159KB
• bmologosm.jpg (GRAPHIC) — 12KB
• 0001214659-26-004400.txt ( ) — 177KB

From the Filing

983 Registration Statement No.333-285508 Filed Pursuant to Rule 433 Subject to Completion, dated April 07, 2026 Pricing Supplement to the Prospectus dated March 25, 2025, the Prospectus Supplement dated March 25, 2025 and the Product Supplement dated March 25, 2025 US$ [ ] Senior Medium-Term Notes, Series K Barrier Notes due April 13, 2029 Linked to the Least Performing of the shares of the Invesco QQQ Trust SM , Series 1 and the shares of the State Street ® SPDR ® S&P 500 ® ETF Trust · The notes are designed for investors who seek periodic interest payments at the interest rate (the "Interest Rate") of 0.5833% per month (approximately 7.00% per annum). Investors should be willing to forego any potential to participate in the appreciation of the shares of the Invesco QQQ Trust SM , Series 1 and the shares of the State Street ® SPDR ® S&P 500 ® ETF Trust (each, a "Reference Asset" and, collectively, the "Reference Assets"), and be willing to lose some or all of their principal at maturity. · The notes will pay a Coupon on each Coupon Payment Date at the Interest Rate. · The notes do not guarantee any return of principal at maturity. Instead, the payment at maturity will be based on the Final Level of the Least Performing Reference Asset (as defined below) and whether the Final Level of any Reference Asset has declined from its Initial Level to below its Trigger Level on the Valuation Date (a “Trigger Event”), as described below. · If a Trigger Event has occurred, you will receive a delivery of shares of the Least Performing Reference Asset (the “Physical Delivery Amount”) or, at our election, the cash equivalent (calculated as described below, the “Cash Delivery Amount”), which will be worth less than the principal amount. Specifically, the value of any Physical Delivery Amount or Cash Delivery Amount that you receive will decrease 1% for each 1% decrease in the level of the Least Performing Reference Asset from its Initial Level to its Final Level. Any fractional shares included in the Physical Delivery Amount will be paid in cash. · Investing in the notes is not equivalent to a direct investment in the Reference Assets. · The notes will not be listed on any securities exchange. · All payments on the notes are subject to the credit risk of Bank of Montreal. · The notes will be issued in minimum denominations of $5,000 and integral multiples of $5,000. · Citigroup Global Markets Inc. (“Citigroup”), is the agent for this offering. See “Supplemental Plan of Distribution (Conflicts of Interest)” below. · The notes will not be subject to conversion into our common shares or the common shares of any of our affiliates under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act (the “CDIC Act”). Terms of the Notes: 1 Pricing Date: April 08, 2026 Valuation Date: April 10, 2029 Settlement Date: April 13, 2026 Maturity Date: April 13, 2029 1 Expected. See “Key Terms of the Notes” below for additional details. Specific Terms of the Notes: Series Number Reference Assets Ticker Symbol Initial Level Interest Rate Trigger Level CUSIP/ISIN Principal Amount Price to Public 1 Agent’s Commission 1 Proceeds to Bank of Montreal 1 983 The shares of the Invesco QQQ Trust SM , Series 1 QQQ [ ] 0.5833% per month (approximately 7.00% per annum) [ ], 70.00% of its Initial Level 06370EFE3 / US06370EFE32 [ ] 100% Up to 2.00% [ ] At least 98.00% [ ] The shares of the State Street ® SPDR ® S&P 500 ® ETF Trust SPY [ ] [ ], 70.00% of its Initial Level 1 The total “Agent’s Commission” and “Proceeds to Bank of Montreal” to be specified above will reflect the aggregate amounts at the time Bank of Montreal establishes its hedge positions on or prior to the Pricing Date, which may be variable and fluctuate depending on market conditions at such times. Certain dealers who purchased the notes for sale to certain fee-based advisory accounts may forego some or all of their selling concessions, fees or commissions. The public offering price for investors purchasing the notes in these accounts may be between $4,900.00 and $5,000 per $5,000 in principal amount. We or one of our affiliates may also pay a referral fee to certain dealers in connection with the distribution of the notes. Investing in the notes involves risks, including those described in the “Selected Risk Considerations” section beginning on page P-5 hereof, the “Additional Risk Factors Relating to the Notes” section beginning on page PS-6 of the product supplement, and the “Risk Factors” section beginning on page S-1 of the prospectus supplement and on page 8 of the prospectus. Neithe